You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 118 No. 6, June 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Case Reports and Small Case Series
 This Article
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on ISI (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Interferon alfa Therapy Against Metastatic Iris Tumor of Renal Cell Carcinoma

Arch Ophthalmol. 2000;118:846-847.

Ocular metastasis of renal cell carcinoma is rare, and metastasis to the iris or ciliary body is especially uncommon. Ferry and Font1 studied 227 cases of metastatic tumors of the eye and orbit and reported that 26 (11.5%) of these lesions were iris or ciliary body tumors and that 2 (0.9%) originated in the kidney. We examined a patient with an iris tumor that metastasized from a renal cell carcinoma and observed marked effects of interferon alfa administration.

Report of a Case

A 55-year-old man was seen on September 3, 1992, with a 1-week history of decreased vision in his right eye. His history included radical right nephrectomy for renal cell carcinoma in December 1990 and left partial pneumonectomy due to lung metastasis in June 1992.

The corrected visual acuity was 20/20 OU and the intraocular pressure was 11 mm Hg OU. Slitlamp biomicroscopy showed cells in the anterior chamber and a well-circumscribed solid tumor (8 x 4 mm) in the iris of the right eye (Figure 1). The mass was vividly red and contained prominent internal blood vessels. Satisfactory visualization of the entire right fundus was not possible because of insufficient mydriasis, but a retinal detachment was noted in the periphery between the 3- and 7-o'clock positions. B-scan ultrasonography revealed a ciliary body mass at the inferonasal part of the ciliary body. No abnormality was noted in the left eye.



View larger version (44K):
[in this window]
[in a new window]
Figure 1. Left, A well-circumscribed solid tumor, which appeared vividly red and contained prominent internal blood vessels, is observed on the iris between the 3- and 7-o'clock positions. Right, The tumor appeared to be totally regressed and white 16 weeks after the beginning of interferon alfa administration.


Systemic examination revealed swelling of the cervical lymph nodes, and results of computed tomographic scans and magnetic resonance images of the head disclosed a cerebral tumor in the right occipital lobe. Biopsy of the cervical lymph nodes established lymph node metastasis of the renal cell carcinoma (Figure 2). Because neurological symptoms such as disturbance of consciousness appeared thereafter, the brain tumor was resected on October 8, and the tumor was confirmed histopathologically to be a metastasis of the renal cell carcinoma.



View larger version (117K):
[in this window]
[in a new window]
Figure 2. Light microscopic appearance of lymph node metastasis displaying sheets of polyhedral-shaped cells with clear cytoplasm (hematoxylin-eosin, original magnification x100).


Systemic interferon alfa was started on October 23 for conservative treatment of the iris tumor. The dose was set initially at 21,000,000 U/wk, but it was reduced to 9,000,000 U/wk in the second week due to bone marrow suppression (decrease in white blood cells and platelets) and to 6,000,000 U/wk in and after the third week. The iris tumor began to regress about 3 weeks after the beginning of interferon alfa administration, and it appeared totally regressed and white after 16 weeks (Figure 1). The retinal detachment disappeared, and the ultrasonographically demonstrated tumor in the ciliary region was not detected. However, the tumor metastasized to the lung, liver, and bones thereafter, and the patient died on June 20, 1993.


Comment

Renal cell carcinoma accounts for 80% to 85% of the malignant tumors of the kidney.2 Metastases were reported to be present in 25% to 30% of patients with renal cell carcinoma at the initial examination.2 Metastases of renal cell carcinoma are hematogenous and lymphogenous, and the lungs are the most frequent site of the distant metastases, followed by metastases to bones, liver, and brain.2 Metastases to the eye are rare, and those to the iris have been documented in only a few cases, including those reported by Ferry and Font1 and Wyzinski et al.3 The iris tumor of our patient appeared vividly red through the biomicroscope (Figure 1). This color has been recognized by some clinicians as characteristic of many metastatic ocular tumors from renal cell carcinoma. Our patient was treated conservatively because no reduction of vision or secondary glaucoma due to the tumor was noted, and because the prognosis was poor due to multiple organ metastases.

Renal cell carcinoma resists routine chemotherapy and radiotherapy.2 However, since interferon alfa has recently been reported to have a direct antiproliferative effect on renal tumor cells in vitro,4 and to stimulate host mononuclear cells and enhance the expression of major-histocompatibility-complex molecules,2 it has been introduced as a new treatment for renal cell carcinoma. More recently, the effects of interferon alfa when used in combination with interleukin 2 and fluorouracil, or with 13-cis-retinoic acid, have been evaluated.2 The response rate of patients to interferon alfa alone is considered to be about 20%, and its therapeutic effect is limited when it is used alone. However, as some patients such as ours show marked responses, interferon alfa may be useful in patients with intraocular metastases of renal cell carcinoma.


AUTHOR INFORMATION

Tomohiro Ikeda, MD; Keiko Sato, MD; Takanobu Tokuyama, MD
Osaka, Japan

Corresponding author: Tomohiro Ikeda, MD, Department of Ophthalmology, Osaka City General Hospital, 2-13-22, Miyakojimahondori, Miyakojima-ku, Osaka 534-0021, Japan (e-mail: tikeda{at}a2.mbn.or.jp).


REFERENCES

1. Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit, II: a clinicopathological study of 26 patients with carcinoma metastatic to the anterior segment of the eye. Arch Ophthalmol. 1975;93:472-482. FREE FULL TEXT
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875. FREE FULL TEXT
3. Wyzinski P, Rootman J, Wood W. Simultaneous bilateral iris metastases from renal cell carcinoma. Am J Ophthalmol. 1981;92:206-209. ISI | PUBMED
4. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP. Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res. 1990;50:4190-4194. FREE FULL TEXT


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.